Abstract 2927
Background
Cancer, which is included in the scope of chronic diseases, affects the lifestyle and quality of the individuals, who got diagnosed, and their familes due to the disease course and treatment method. According to the "theory of family systems", when a disease occurs in the individual, the whole family is affected by the disease, not only patient. It is suggested that families should not be seen as a passive shelter for patients, they should also as a human unity living at the same time as the cancer crisis. In cancer care, caregivers have many responsibilities, from diagnosis to the end of life. While there are studies conducted to evaluate the quality of life of cancer patients in Turkey and other countries, there are a limited number of studies evaluating the quality of life of caregivers of cancer patients. It was aimed to performed in our country for validity and reliability of "Singapore Caregiver Quality Of Life Scale", which was planned based on this deficiency, and to be a guide for the evaluation of the quality of the life of the relatives or carers of different cultures, different ethnic groups and determining the nursing care strategies.
Methods
This study, which was planned as a methodological and descriptive study, was caried out with 550 caregivers in two university hospitals in Izmir. The data were collected by using the Individual Presentation Form, Singapore Caregiver Quality of Life Scale and Quality of Life Scale in Cancer Patients Family Version. Written informed consent was obtained from hospitals and individuals.
Results
The analysis of the findings is ongoing and will be shared in the full text.
Conclusions
Quality of life of caregivers of cancer patients is an important indicator of the quality of life of the patient. In this study, Turkish validation sfudies of the "Singapore Caregiver Quality Of Life Scale" were conducted. The results will be shared later.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Presenter: Anouk de Jong
Session: Poster Display session 3
Resources:
Abstract
2226 - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)
Presenter: Glenn Liu
Session: Poster Display session 3
Resources:
Abstract
5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.
Presenter: Susanne Osanto
Session: Poster Display session 3
Resources:
Abstract
899 - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Presenter: Jungreem Woo
Session: Poster Display session 3
Resources:
Abstract
3094 - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
2527 - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)
Presenter: Rebeca Lozano Mejorada
Session: Poster Display session 3
Resources:
Abstract
6106 - Assessing the clinical relevance of drug–drug interactions (DDI) with darolutamide (DARO)
Presenter: Christian Zurth
Session: Poster Display session 3
Resources:
Abstract
2237 - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
2241 - KEYNOTE-641: Phase 3 Study of Pembrolizumab (pembro) Plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: Julie Graff
Session: Poster Display session 3
Resources:
Abstract